SCI Pharmtech Financials
| 4119 Stock | TWD 95.50 2.10 2.15% |
SCI |
Understanding current and past SCI Pharmtech Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of SCI Pharmtech's financial statements are interrelated, with each one affecting the others. For example, an increase in SCI Pharmtech's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in SCI Pharmtech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of SCI Pharmtech. Check SCI Pharmtech's Beneish M Score to see the likelihood of SCI Pharmtech's management manipulating its earnings.
SCI Pharmtech Stock Summary
SCI Pharmtech competes with Grape King, Standard Chemical, Adimmune Corp, ScinoPharm Taiwan, and Excelsior Medical. SCI Pharmtech, Inc. develops, produces, and sells active pharmaceutical ingredients, intermediates, and specialty chemicals in Taiwan. SCI Pharmtech, Inc. was founded in 1987 and is based in Taoyuan City, Taiwan. SCI PHARMTECH operates under Drug Manufacturers - Specialty Generic classification in Taiwan and is traded on Taiwan Stock Exchange.| Instrument | Taiwan Stock View All |
| Exchange | Taiwan Stock Exchange |
| ISIN | TW0004119003 |
| Business Address | No 61, Haihu |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.sci-pharmtech.com.tw |
| Phone | 886 3 354 3133 |
| Currency | TWD - New Taiwan Dollar |
You should never invest in SCI Pharmtech without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of SCI Stock, because this is throwing your money away. Analyzing the key information contained in SCI Pharmtech's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
SCI Pharmtech Key Financial Ratios
There are many critical financial ratios that SCI Pharmtech's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that SCI Pharmtech reports annually and quarterly.| Return On Equity | 0.0609 | |||
| Return On Asset | 0.0077 | |||
| Target Price | 86.0 | |||
| Number Of Employees | 14 | |||
| Beta | -0.0933 |
SCI Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining SCI Pharmtech's current stock value. Our valuation model uses many indicators to compare SCI Pharmtech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across SCI Pharmtech competition to find correlations between indicators driving SCI Pharmtech's intrinsic value. More Info.SCI Pharmtech is rated fourth in return on equity category among its peers. It is rated fifth in return on asset category among its peers reporting about 0.13 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for SCI Pharmtech is roughly 7.91 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the SCI Pharmtech's earnings, one of the primary drivers of an investment's value.SCI Pharmtech Systematic Risk
SCI Pharmtech's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. SCI Pharmtech volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was four with a total number of output elements of fifty-seven. The Beta measures systematic risk based on how returns on SCI Pharmtech correlated with the market. If Beta is less than 0 SCI Pharmtech generally moves in the opposite direction as compared to the market. If SCI Pharmtech Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one SCI Pharmtech is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of SCI Pharmtech is generally in the same direction as the market. If Beta > 1 SCI Pharmtech moves generally in the same direction as, but more than the movement of the benchmark.
SCI Pharmtech November 27, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of SCI Pharmtech help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of SCI Pharmtech. We use our internally-developed statistical techniques to arrive at the intrinsic value of SCI Pharmtech based on widely used predictive technical indicators. In general, we focus on analyzing SCI Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build SCI Pharmtech's daily price indicators and compare them against related drivers.
| Downside Deviation | 0.7461 | |||
| Information Ratio | (0.03) | |||
| Maximum Drawdown | 4.35 | |||
| Value At Risk | (0.67) | |||
| Potential Upside | 1.34 |
Additional Tools for SCI Stock Analysis
When running SCI Pharmtech's price analysis, check to measure SCI Pharmtech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SCI Pharmtech is operating at the current time. Most of SCI Pharmtech's value examination focuses on studying past and present price action to predict the probability of SCI Pharmtech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SCI Pharmtech's price. Additionally, you may evaluate how the addition of SCI Pharmtech to your portfolios can decrease your overall portfolio volatility.